Embolic protection device

Information

  • Patent Grant
  • 8632562
  • Patent Number
    8,632,562
  • Date Filed
    Monday, October 2, 2006
    18 years ago
  • Date Issued
    Tuesday, January 21, 2014
    11 years ago
Abstract
An embolic protection device for deployment in a body vessel is provided for filtering emboli within the body vessel. The embolic protection device generally includes a filter having a plurality of openings formed therethrough and an extraction element configured to be movable with respect to the filter between a non-extraction position and an extraction position. The extraction element is located distally of the filter when in the non-extraction position so as to allow the filter to open into an expanded state to collect the emboli. Additionally, the extraction element is disposed about at least a portion of the filter when in the extraction position so as to close the filter into a collapsed state and to permit the embolic protection device to be extracted from the body vessel.
Description
BACKGROUND

1. Field of the Invention


The invention relates generally to medical devices. More specifically, the invention relates to intravascular embolic protection devices.


2. Related Technology


Embolic protection devices are percutaneously placed in a body vessel to prevent emboli from traveling and creating an undesirable embolism, e.g., pulmonary embolism. For example, vena cava filters are being used for trapping emboli in the vena cava filter to prevent pulmonary embolism. Also, anti-platelet agents and anticoagulants may be used to breakdown blood clots. Moreover, snares and baskets (e.g., stone retrieval baskets) are being used for retrieving urinary calculi. Additionally, occlusion coils are commonly used to occlude aneurysms and accumulate thrombi in a body vessel.


Treatments for a stenotic lesion provide a potential in releasing blood clots and other thrombi plaque in the vasculature of the patient. One example is the treatment for a carotid artery stenosis. Generally, carotid artery stenosis is the narrowing of the carotid arteries, the main arteries in the neck that supply blood to the brain. Carotid artery stenosis (also called carotid artery disease) is a relatively high risk factor for ischemic stroke. The narrowing is usually caused by plaque build-up in the carotid artery.


Carotid angioplasty is a more recently developed treatment for carotid artery stenosis. This treatment uses balloons and/or stents to open a narrowed portion of an artery. Carotid angioplasty is a procedure that can be performed via a standard percutaneous transfemoral approach with the patient anesthetized using light intravenous sedation. At the stenosis area, an angioplasty balloon is delivered to predilate the stenosis in preparation for stent placement. The balloon is then removed and exchanged via catheter for a stent delivery device. Once in position, a stent is deployed across the stenotic area. If needed, an additional balloon can be placed inside the deployed stent for post-dilation to make sure the struts of the stent are pressed firmly against the inner surface of the vessel wall. During the stenosis procedure however, such as during the predilation or during the stent delivery, there is a risk of such blood clots and thrombi being undesirably released into the blood flow within the vasculature.


Therefore, embolic protection devices, such as occlusive devices and filters, have been developed to trap and to prevent the downstream travel of the blood clots and thrombi. The filters are typically advanced downstream of a site that is to be treated and then expanded into an opened state to increase the filter area. The blood clots and thrombi can be captured in the opened filter while blood is still able to flow therethrough.


Once the stenosis procedure has been completed, the stent delivery device is removed from the stenotic area and is possibly removed completely from the body vessel. Next, after the blood clots and thrombi displaced by the angioplasty have been captured in the opened filter, the embolic protection device is removed from the body vessel. However, to prevent the captured blood clots and thrombi from being released back into the blood stream, the embolic protection device preferably includes a mechanism for securing the blood clots and thrombi during removal of the embolic protection device. Furthermore, to facilitate the removal of the embolic protection device and to minimize or prevent additional blood clots and thrombi from being released from the stenotic area, the embolic protection device preferably has a relatively small cross-sectional area during the removal thereof.


However, currently known filter devices may fail to completely secure the blood clots and thrombi during removal of the embolic protection device. As another drawback, currently known filter devices may not sufficiently radially collapse the filter device before or during extraction from the body vessel. Additionally, or alternatively, currently known filter devices may require relatively bulky components to employ or control the mechanism for securing the blood clots and thrombi.


Thus, there is a need to improve the cross-sectional size of the embolic protection device during extraction from the body vessel and a need to improve the mechanism for securing the blood clots and thrombi during the extraction.


SUMMARY

In one aspect of the present invention, an embolic protection device for deployment in a body vessel is provided for filtering emboli within the body vessel. The embolic protection device generally includes a filter having a plurality of openings formed therethrough and an extraction element configured to be movable with respect to the filter between a non-extraction position and an extraction position. The extraction element is located distally from the filter when in the non-extraction position so as to allow the filter to open into an expanded state to collect the emboli. Additionally, the extraction element is disposed about at least a portion of the filter when in the extraction position so as to close the filter into a collapsed state, to secure the collected emboli, and to permit the embolic protection device to be extracted from the body vessel.


In another aspect of the invention, the extraction element is an extraction sleeve. As an alternative design, the extraction element includes an extraction wire defining a loop. The extraction wire also may define a plurality of closed loops that are movable with respect to each other. In yet another alternative design, the extraction wire defines a coiled wire.


In yet another aspect, the filter includes a first filter element and a second filter element spaced apart from each other. Additionally, the first filter element defines a plurality of first filter openings and the second filter element defines a plurality of second filter openings, where the first filter openings are each larger than the second filter openings. The filter may also include a third filter element spaced apart from the first and the second filter elements.


In another aspect, the first filter openings decrease in size between a proximal portion and a distal portion of the first filter element and the second filter openings decrease in size between a proximal portion and a distal portion of the second filter element. This configuration promotes a complete self-expansion of each of the filter elements within the body vessel.


In yet another aspect of the present invention, the embolic protection device includes a delivery element that is movable with respect to the filter between a delivery position and a non-delivery position. The delivery element is disposed about at least a portion of the filter when in the delivery position so that the filter is in a collapsed state for delivery of the embolic protection device within the body vessel. Additionally, the delivery element is located proximally from the filter when in the non-delivery position so as to allow the filter to open into an expanded state and facilitate collection of the emboli.


The embolic protection device may also include: a filter control wire coupled with the filter to control the position thereof, an extraction control wire coupled with the extraction element to control the position thereof, and a delivery control wire coupled with the delivery element and to control the position thereof. In one design, the filter control wire is a hollow wire defining a conduit that receives at least a portion of the extraction control wire and at least a portion of the delivery control wire. Additionally, the outer diameter of the filter control wire is preferably substantially greater than each of the outer diameters of the extraction control wire and the delivery control wire.


In another aspect of the present invention, an assembly for removing emboli from a body vessel is provided. The assembly generally includes an inflatable catheter having an expanded state for expanding narrowed or restricted portions of the body vessel, an outer catheter for delivering the inflatable catheter into the body vessel, and an embolic protection device positioned distally of the inflatable catheter for collecting emboli that are potentially dislodged during expansion of the body vessel.


In another aspect of the present invention, an embolic protection device includes a first filter element and a second filter element, each having a proximal end and a distal end. The proximal end of the second filter element is connected to an outer surface of the first filter element to stabilize the filter elements and to prevent emboli from flowing around the embolic protection device.


The first filter element and the second filter element preferably overlap each other to define an overlapping distance along the longitudinal axis of the embolic protection device. Additionally, or alternatively, the embolic protection device includes a third filter element having a proximal end and a distal end, wherein the proximal end of the third filter element is connected to an outer surface of the second filter element. The three filter elements cooperate to define a substantially constant outer diameter between the proximal end of the first filter element and the distal end of the third filter element.


The second plurality of openings are generally smaller than the first plurality of openings and the third plurality of openings are generally smaller than the second plurality of openings so that the first filter element collects relatively large emboli, the second filter element collects medium-sized emboli, and the third filter element collects relatively small emboli.


Further objects, features and advantages of this invention will become readily apparent to persons skilled in the art after a review of the following description, with reference to the drawings and claims that are appended to and form a part of this specification.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an environmental side view of an embolic protection device in a collapsed state for delivery within a blood vessel in accordance with one embodiment of the present invention;



FIG. 2 is an environmental side view of the embolic protection device in FIG. 1 shown in an expanded state;



FIG. 3 is an environmental side view of the embolic protection device in FIG. 2 shown in conjunction with an inflatable catheter in a partially-expanded state so as to contact a stenotic lesion;



FIG. 4 is an environmental side view of the embolic protection device in FIG. 3 with the inflatable catheter in a completely expanded state, potentially dislodging emboli from the stenotic lesion;



FIG. 5 is an environmental side view of the embolic protection device in FIG. 4 with the inflatable catheter in a deflated state for extraction from the blood vessel;



FIG. 6 is an environmental side view of the embolic protection device in FIG. 5 in the collapsed state for extraction from the blood vessel;



FIG. 7 is an enlarged portion of the embolic protection device indicated by line 7-7 in FIG. 4;



FIG. 8 is a cross-sectional view of the embolic protection device taken along line 8-8 in FIG. 7;



FIG. 9 is an enlarged portion of the embolic protection device indicated by line 9-9 in FIG. 6 showing a filter control wire and a delivery control wire;



FIG. 10 is a cross-sectional view of the embolic protection device taken along line 10-10 in FIG. 9;



FIG. 11 is a cross-sectional view of the embolic protection device taken along line 11-11 in FIG. 9;



FIG. 12 is an environmental side view of an alternative embolic protection device in an expanded state for collecting emboli from the blood stream in accordance with one embodiment of the present invention;



FIG. 13 is an environmental side view of the embolic protection device from FIG. 12 in a collapsed state for extraction from the blood vessel;



FIG. 14 is an environmental side view of yet another alternative embolic protection device in an expanded state for collecting emboli from the blood stream in accordance with one embodiment of the present invention;



FIG. 15 is an environmental side view of the embolic protection device from FIG. 14 in a collapsed state for extraction from the blood vessel;



FIG. 16 is an environmental side view of another alternative embolic protection device in an expanded state in accordance with one embodiment of the present invention; and



FIG. 17 is an environmental side view of the embolic protection device from FIG. 16 in a collapsed state for extraction from the blood vessel.





DETAILED DESCRIPTION

Embodiments of the present invention generally provide embolic protection devices, embolic protection apparatus, and methods for capturing emboli in a body vessel during angioplasty for treatment of a stenosis. One particular stenosis is a carotid artery stenosis. The embodiments reduce the concerns of current stenosis treatments, such as the relatively high risks of surgery and the potential release of emboli into the vasculature during the stenosis procedure. For example, embodiments of the present invention provide a relatively low risk approach to capturing emboli released during a stenosis procedure, e.g., balloon angioplasty.


Referring now to the drawings, FIGS. 1-6 show an embolic protection device 20 to be positioned within a body vessel, such as a blood vessel 22, for filtering emboli 24 (FIG. 4) from a blood stream 25. More specifically, the embolic device 20 includes a filter 26 positioned downstream of emboli 24, such as blood clots and plaque fragments, to trap and prevent the downstream travel of the emboli 24 and reduce the likelihood of downstream blood vessels becoming blocked. As will be discussed in more detail below, the filter 26 includes a plurality of openings 28 that permit blood to flow therethrough and that prevent the emboli 24 from doing the same. As will also be discussed in more detail below, the filter 26 preferably includes three filter elements 26a, 26b, 26c spaced apart from each other in series.


The filter elements 26a, 26b, 26c each preferably include an open, proximally-located lip portion 30a, 30b, 30c that selectively expands to receive the emboli 24 and a closed, distally-located base portion 36a, 36b, 36c to collect and/or store the emboli 24. The lip portion 30a, 30b, 30c is movable so that the embolic protection device 20 defines a collapsed state 32 (FIGS. 1 & 6) and an expanded state 34 (FIGS. 2 through 5). The expanded state 34 filter 26 is able to collect and trap emboli 24 within the respective filter elements 26a, 26b, 26c, while the collapsed state 32 filter 26 is able to be inserted and withdrawn from the blood vessel 22, as will be discussed in more detail below.


The filter 26, when in the expanded state 34, preferably has a generally decreasing radius such that a first cross-sectional area of the filter 26 taken along a plane adjacent to the lip portion 30 is substantially larger than a second cross-sectional area of the filter 26 taken along a second plane adjacent to the base portion 36. For example, the expanded state 34 filter 26 is preferably generally cone-shaped such as to have a constantly decreasing radius along a longitudinal axis. In the design shown in the figures, each of the individual filter elements 26a, 26b, 26c is generally cone-shaped.


The filter 26 may be made of any suitable filter material to be used for capturing emboli 24 from the stenotic lesion during treatment thereof. In one embodiment, the filter 26 is coated with or made of reconstituted or naturally-derived collagenous materials. Such materials that are at least bioresorbable will provide advantage in the present invention, with materials that are bioremodelable and promote cellular invasion and ingrowth providing particular advantage.


Suitable bioremodelable materials can be provided by collagenous extracellular matrix materials (ECMs) possessing biotropic properties, including in certain forms angiogenic collagenous extracellular matrix materials. For example, suitable collagenous materials include ECMs such as submucosa, renal capsule membrane, dermal collagen, dura mater, pericardium, fascia lata, serosa, peritoneum or basement membrane layers, including liver basement membrane. Suitable submucosa materials for these purposes include, for instance, intestinal submucosa, including small intestinal submucosa, stomach submucosa, urinary bladder submucosa, and uterine submucosa.


As prepared, the submucosa material and any other ECM used may optionally retain growth factors or other bioactive components native to the source tissue. For example, the submucosa or other ECM may include one or more growth factors such as basic fibroblast growth factor (FGF-2), transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), and/or platelet derived growth factor (PDGF). As well, submucosa or other ECM used in the invention may include other biological materials such as heparin, heparin sulfate, hyaluronic acid, fibronectin and the like. Thus, generally speaking, the submucosa or other ECM material may include a bioactive component that induces, directly or indirectly, a cellular response such as a change in cell morphology, proliferation, growth, protein or gene expression.


Submucosa or other ECM materials of the present invention can be derived from any suitable organ or other tissue source, usually sources containing connective tissues. The ECM materials processed for use in the invention will typically include abundant collagen, most commonly being constituted at least about 80% by weight collagen on a dry weight basis. Such naturally-derived ECM materials will for the most part include collagen fibers that are non-randomly oriented, for instance occurring as generally uniaxial or multi-axial but regularly oriented fibers. When processed to retain native bioactive factors, the ECM material can retain these factors interspersed as solids between, upon and/or within the collagen fibers. Particularly desirable naturally-derived ECM materials for use in the invention will include significant amounts of such interspersed, non-collagenous solids that are readily ascertainable under light microscopic examination with specific staining. Such non-collagenous solids can constitute a significant percentage of the dry weight of the ECM material in certain inventive embodiments, for example at least about 1%, at least about 3%, and at least about 5% by weight in various embodiments of the invention.


The submucosa or other ECM material used in the present invention may also exhibit an angiogenic character and thus be effective to induce angiogenesis in a host engrafted with the material. In this regard, angiogenesis is the process through which the body makes new blood vessels to generate increased blood supply to tissues. Thus, angiogenic materials, when contacted with host tissues, promote or encourage the infiltration of new blood vessels. Methods for measuring in vivo angiogenesis in response to biomaterial implantation have recently been developed. For example, one such method uses a subcutaneous implant model to determine the angiogenic character of a material. See, C. Heeschen et al., Nature Medicine 7 (2001), No. 7, 833-839. When combined with a fluorescence microangiography technique, this model can provide both quantitative and qualitative measures of angiogenesis into biomaterials. C. Johnson et al., Circulation Research 94 (2004), No. 2, 262-268.


Further, in addition or as an alternative to the inclusion of native bioactive components, non-native bioactive components such as those synthetically produced by recombinant technology or other methods, may be incorporated into the submucosa or other ECM tissue. These non-native bioactive components may be naturally-derived or recombinantly produced proteins that correspond to those natively occurring in the ECM tissue, but perhaps of a different species (e.g. human proteins applied to collagenous ECMs from other animals, such as pigs). The non-native bioactive components may also be drug substances. Illustrative drug substances that may be incorporated into and/or onto the ECM materials used in the invention include, for example, antibiotics or thrombus-promoting substances such as blood clotting factors, e.g. thrombin, fibrinogen, and the like. These substances may be applied to the ECM material as a premanufactured step, immediately prior to the procedure (e.g. by soaking the material in a solution containing a suitable antibiotic—such as cefazolin), or during or after engraftment of the material in the patient.


Submucosa or other ECM tissue used in the invention is preferably highly purified, for example, as described in U.S. Pat. No. 6,206,931 to Cook et al. Thus, preferred ECM material will exhibit an endotoxin level of less than about 12 endotoxin units (EU) per gram, more preferably less than about 5 EU per gram, and most preferably less than about 1 EU per gram. As additional preferences, the submucosa or other ECM material may have a bioburden of less than about 1 colony forming units (CFU) per gram, more preferably less than about 0.5 CFU per gram. Fungus levels are desirably similarly low, for example less than about 1 CFU per gram, more preferably less than about 0.5 CFU per gram. Nucleic acid levels are preferably less than about 5 μg/mg, more preferably less than about 2 μg/mg, and virus levels are preferably less than about 50 plaque forming units (PFU) per gram, more preferably less than about 5 PFU per gram. These and additional properties of submucosa or other ECM tissue taught in U.S. Pat. No. 6,206,931 may be characteristic of the submucosa tissue used in the present invention.


In this embodiment, the submucosa or other ECM material is used to temporarily adhere the filter 26 to the walls of a body vessel in which the embolic protection device 20 is deployed. As discussed above, the submucosa or other ECM material has a natural adherence or wettability to body fluids and connective cells comprising the connective tissue of a body vessel wall. Due to the temporary nature of the duration in which the embolic protection device 20 is deployed in the body vessel, host cells of the wall will adhere to the filter 26 but not differentiate, allowing for retrieval of the embolic protection device 20 from the blood vessel 22.


In other embodiments, the filter 26 may also or alternatively be made of a mesh/net cloth, nylon, polymeric material, Teflon, or woven mixtures thereof without falling beyond the scope or spirit of the present invention.


Each of the filter elements 26a, 26b, 26c also preferably includes a plurality of struts 38 (FIGS. 2-5 and 7) for supporting the filter material. For example, the struts 38 extend from the base portion 36 to the lip portion 30 of each of the filter elements 26a, 26b, 26c and are generally circumferentially evenly-spaced from each other at the lip portion 30. Additionally, the struts 38 are secured to an inner surface of the filter material such that the filter material and the struts 38 collapse and expand in unison.


The struts 38 may be comprised of any suitable material such as a superelastic material, stainless steel wire, cobalt-chromium-nickel-molybdenum-iron alloy, or cobalt-chrome alloy. It is understood that the struts 38 may be formed of any other suitable material, such as shape memory alloys. Shape memory alloys have the desirable property of returning to a remembered state when heated above a transition temperature. A shape memory alloy suitable for the present invention is a mixture of Nickel and Titanium available under the more commonly known name Nitinol. When this material is heated above the transition temperature, the material undergoes a phase transformation from martensite to austenic, such that material returns to its remembered state. The transition temperature is dependent on the relative proportions of the alloying elements Nickel and Titanium and the optional inclusion of alloying additives.


In one embodiment, the struts 38 are made from Nitinol with a transition temperature that is slightly below normal body temperature of humans, which is about 98.6 degrees Fahrenheit. Therefore, when the filter 26 is deployed in the blood vessel 22 and exposed to normal body temperature, the alloy of the struts 38 will transform to austenite, that is, the remembered state, which for one embodiment of the present invention is the expanded configuration when the filter 26 is deployed in the blood vessel 22, as will be discussed in more detail below.


Each of the filter elements 26a, 26b, 26c also preferably includes a frame 40 positioned at or adjacent to the lip portion 30a, 30b, 30c to form a substantially fluid-tight seal with the blood vessel 22. More specifically, when the filter 26 is in the expanded state 34, the frame 40 defines a generally circular shape so as to generally conform to the shape the blood vessel 22. The seal substantially prevents emboli 24 from flowing around the filter 26 and causing the above-described conditions.


However, the frame 40 is also preferably able to be radially collapsed when the filter 26 is in the collapsed state 32. For example, the frame 40 may include a plurality of flexible, telescoping portions so that the frame 40 remains a generally circular component with an adjustable radius, whether the frame 40 is in the collapsed state 32 or the expanded state 34. This design may be particularly advantageous because it allows the embolic protection device 20 to be used in blood vessels 22 of varying size while still retaining a generally circular shape. Alternatively, the frame 40 may include a plurality of generally rigid portions that are hingedly connected with each other so that the frame 40 is generally circular when in the expanded state 34 and is non-circular, such as a star shape, when the frame 26 is in the collapsed state 32. As yet another alternative design, the frame 40 may be a single component with a plurality of weakened portions to permit the frame 40 to collapse into a non-circular shape, such as a star shape, when the frame 26 is in the collapsed state 32.


In another alternative design, the filter 26 does not include a frame, and the struts 38 provide sole structural support for the filter material. This design may be particularly advantageous because it allows the embolic protection device 20 to be used in blood vessels 22 having varying sizes. In yet another alternative design, the filter 26 does not include a frame or struts, and the filter material is not structurally supported by any additional components. In this design, and preferably in the other designs described herein, the filter material is naturally expanded into the expanded state 34 by forces from the blood stream 25 flowing through the blood vessel 22.


The openings 28 defined by the filter elements 26a, 26b, 26c are preferably configured such as to effectively harness the blood stream 25 and to promote the natural expansion of filter 26. For example, referring to FIGS. 7 and 8, each of the filter elements 26a, 26b, 26c preferably includes proximal openings 42 that have a generally larger cross-sectional area than distal openings 44 to maximize the occluding capacity of the filter 26 and to promote full expansion of filter elements 26a, 26b, 26c within the blood vessel 22, as is discussed in more detail below.


Regarding the base portion 36, the distal openings 44 are relatively small so as to cause a flow resistance that is sufficient to open the filter 26. More specifically, the distal openings 44 are sized and positioned with respect to each other such that the filter 26 provides a flow resistance when the base portion 36 is folded. Therefore, when the filter 26 is in the collapsed state 32, such as when being initially deployed into the blood vessel 22, the filter 26 may become folded along creases such that some of the openings 28 become blocked. Therefore, the distal openings 44 are sized and positioned with respect to each other such as to provide a flow resistance unless substantially all of the distal openings 44 are unobstructed, thereby causing the filter 26 to naturally expand.


However, the distal openings 44 are preferably not so small as to restrict blood flow there through when the base portion 36 is fully opened and unobstructed. As discussed above, restricted blood flow can cause various undesirable medical conditions. Therefore, the distal openings 44 are large enough such as to not reduce blood flow through the filter 26.


The distal openings 44 are preferably located along an end face 46 of the filter 26 that is substantially perpendicular to the direction of the blood stream 25. This configuration also causes the filter 26 to fully open because the openings along the end face 46 have a maximum effective area when positioned to be perpendicular to the blood stream 25. Therefore, the natural properties of fluid flow will cause the end face 46 to be perpendicular to the direction of the blood stream 25, thus opening the filter 26 to its full length and maximizing its trapping volume.


Regarding the lip portion 30, the proximal openings 42 are relatively large to act as overflow passages for the distal openings 44 if they become obstructed. As emboli 24 flow into the filter 26 and engage the base portion 36, the distal openings 44 may become obstructed, thereby limiting the fluid flow through the base portion 36. To compensate for this reduced flow are, the proximal openings 42 have relatively large cross-sections. Therefore, the large proximal openings 42 substantially prevent the embolic protection device 20 from causing flow loss.


As shown in FIGS. 7 and 8, intermediate openings 48 are located axially between the proximal and distal openings 42, 44 such as to define flowpaths there through. The intermediate openings 48 are generally decreasing in size along the axial length in the direction of the blood stream 25. Furthermore, the proximal openings 42 are generally more spaced-apart from each other than the distal openings 44. Additionally, the intermediate openings 48 become generally less spaced-apart along the axial length of the respective filter elements 26a, 26b, 26c in the direction of the blood stream 25.


The proximal openings 42 may serve as continuously-used passages, such that blood continuously flows through the proximal openings 42, whether the distal openings 44 are obstructed or unobstructed. However, due to the generally cone-shaped nature of the filter elements 26a, 26b, 26c, the radially central portion of the filter receives the majority of the flow therethrough. More specifically, the natural fluid properties of the blood flow, such as friction between the blood flow and the blood vessel walls, cause the radially central portion of the blood vessel 22 to have a higher mass flow volume than the radially outer portion of the blood vessel 22. Furthermore, the tapered shape of the filter elements 26a, 26b, 26c directs blood towards the base portion 36 and thus towards the distal openings 44.


In addition to maximizing the trapping volume of and minimizing the flow losses through, the filter 26 also includes features that maximize the radial expansion of the embolic protection device 20. More specifically, to effectively form a seal between the filter 26 and the blood vessel 22 and thus prevent emboli 24 from flowing past the filter 26, the embolic protection device 20 is configured such that blood flow causes the filter 26 to be radially opened until it engages the blood vessel 22 inner walls.


One such feature that radially opens the filter 26 is the generally cone-shaped design of the filter 26. This shape causes blood flow along the direction of the blood stream 25 to create an axial force component 50 and a radial force component 52. More specifically, the axial force component 50 extends the filter 28 along its length, as discussed above. Furthermore, the radial force component 52 extends the filter 26 outwardly in the radial direction, towards the blood vessel 22 inner walls. Therefore, the cone-shaped nature of the filter 26 improves the seal and increases the trapping volume of the device 20.


In the embodiment shown in the figures, another such feature that radially opens the filter 26, or maintains the opened state thereof is the submucosa or other ECM material promoting biofixation between the filter 26 and the body vessel 12 discussed above. More specifically, the outer surface of the filter 26 includes a connective tissue that causes biofixation between the outer surface of the filter 26 and the inner surface of the blood vessel 22, thereby sealing the respective components 26, 22 together. The connective tissue is located on the frame 26 and on a portion of the filter 26 immediately adjacent to the lip portion 30. Additionally, the connective tissue may be located on the outer surface along a length of the filter 26 such as to increase the surface area of the seal. As another design, the connective tissue may be a coating along the entire length of the filter 26. As yet another design, the filter material may be completely formed of the connective tissue.


Referring back to FIGS. 1-6, the filter elements 26a, 26b, 26c are each respectively configured such as to collect emboli 24 of varying sizes and shapes. For example, the first filter element 26a defines a first set of openings 28a having a relatively large size so that only relatively large emboli 24a are collected by the first filter element 26a and smaller emboli are permitted to flow therethrough. Additionally, the second filter element 26b defines a second set of openings 28b having a medium size so that only medium-sized emboli 24b are collected by the second filter element 26b and smaller emboli are permitted to flow therethrough. Furthermore, the third filter element 26c defines a third set of openings 28c having a relatively small size so that the remaining, relatively small emboli 24c are collected by the third filter element 26c and blood cells are permitted to flow therethrough.


In one configuration, each of the openings 28a in the first filter element 26a is larger than each of the openings 28b in the second filter element 26b and each of the openings 28b in the second filter element 26b is larger than each of the openings 28c in the third filter element 26c. In another configuration, the proximal openings in the in the first filter element 26a are larger than the proximal openings in the second filter element 26b and the distal openings in the in the first filter element 26a are larger than the distal openings in the second filter element 26b, but the proximal openings in the first filter element 26a are not larger than the distal openings in the second filter element 26b. In other words, in this configuration, the average size of the openings decreases from the first filter element 26a to the third filter element 26c, but some of the openings in the second or third filter elements 26b, 26c may still be smaller than some of the openings in the first filter element 26a. Alternatively, any suitable configuration of the openings may be used.


The above-described configuration is beneficial for reducing the cross-sectional area of the filter 26 when the emboli 24 are trapped therewithin. In other words, each of the filter elements 26a, 26b, 26c is able to collect a generally equal amount of emboli 24, thereby equally distributing the emboli 24 among the filter elements 26a, 26b, 26c. This configuration is particularly beneficial for reducing the cross-sectional area of the filter 26 when in the collapsed state 32, as will be discussed in more detail below.


Although three filter elements 26a, 26b, 26c are shown in the figures, any suitable number of elements may be used with the present invention. For example, a single filter element may be employed in the embolic protection device 20.


Generally, during use, the device 20 is inserted into the blood vessel 22 while in the collapsed state 32. Additionally, the device 20 is then expanded from the collapsed state 32 to the expanded state 34 so that the filter 26 engages the blood vessel 22. As a result, the lip portion 30 of each of the respective filter elements 26a, 26b, 26c opens for capturing emboli during treatment of the stenotic lesion. After the need for such device 20 in the vasculature passes, the device 20 may be closed to the collapsed state 32 and retrieved.


To illustrate a more specific example, FIGS. 1-6 show an assembly 54 for treatment of a stenotic lesion 66. As shown in FIG. 1, the assembly 54 includes an inflatable catheter 56 in a deflated state 58 and an outer catheter 60 supporting and delivering the inflatable catheter 56 into the blood vessel 22. More specifically, the inflatable catheter 56 includes a tubular body 62 and an expandable balloon 64 attached to and in fluid communication with the tubular body 62 for an angioplasty at the stenotic lesion 66. In this embodiment, the assembly 54 includes the embolic protection device 20 described above. Furthermore, the assembly 54 also includes a filter control wire 68 for guiding the inflatable catheter 56 coupling the embolic protection device 20 thereto.


A method of utilizing the assembly 54 will now be discussed in more detail. First, as shown in FIG. 1, the filter control wire 68 is inserted percutaneously into the blood vessel 22 and advanced therealong, past the stenotic lesion 66. The filter control wire 68 may be advanced along an already-inserted wire guide (not shown) known in the art or may be advanced solely along the blood vessel 22. Next, the outer catheter 60 is percutaneously inserted into the blood vessel 22 and advanced along the filter control wire 68 until positioned at a desired location, which is preferably proximal of the stenotic lesion 66. The embolic protection device 20 is then advanced from the outer catheter 60 to a desired location, which is preferably distal of the stenotic lesion 66. At this point, the filter 26 is in the collapsed state 32, preferably due to the presence of a delivery sleeve 70 in a delivery position 72, as will be discussed in more detail below. Next, or simultaneously with the advancing of the embolic protection device 20, the assembly 54 is advanced to a desired location such that the expandable balloon 64, still in the deflated state 58, is aligned with the stenotic lesion 66.


Next, as shown in FIG. 2, the delivery sleeve 70 is moved from the delivery position 72 to a non-delivery position 74 that is between the stenotic lesion 66 and the filter 26 so that the filter elements 26a, 26b, 26c are able to expand into the expanded state 34, as discussed above. More specifically, each of the filter elements 26a, 26b, 26c expands to contact an inner wall 76 of the blood vessel 22 and form a generally fluid-tight seal therewith. The filter elements 26a, 26b, 26c preferably expand due to natural forces, such as the shape memory forces or the blood stream 25 forces discussed above.


The seal preferably prevents emboli 24 from flowing between the filter 26 and the blood vessel inner wall 76, thereby preventing or minimizing the above-described conditions. The delivery sleeve 70 is preferably moved with respect to the filter 26 via a delivery control wire 78 that is able to be retracted with respect to the filter control wire 68, as will be discussed in more detail below. Although the delivery sleeve 70 is shown as being positioned between the stenotic lesion 66 and the filter 26 when in the non-delivery position 74, any suitable non-delivery position may be used. For example, the delivery sleeve 70 may be retracted over the assembly 54 and completely removed from the blood vessel 22.


Next, the expandable balloon 64 is expanded into a partially-expanded state 80 (FIG. 3) so that it contacts the stenotic lesion 66 and is further expanded into an expanded state 82 (FIG. 4) so that it expands the body vessel 22 in the area of the stenotic lesion 66. As mentioned above, the expansion of the body vessel 22 potentially causes the release of emboli 24 into the blood stream, which are captured by the filter elements 26a, 26b, 26c. The expandable balloon 64 is preferably expanded by a fluid, such as water or saline solution, which is injected along the tubular body 62 into the expandable balloon 64. More specifically, the tubular body 62 preferably has a ring-shaped cross-section, not unlike a doughnut, so that the filter control wire 68 is able to travel through the central opening of the tubular body 62 and so that the fluid is able to travel along a conduit surrounding the filter control wire 68. At this point in the procedure, the filter 26 preferably remains in the expanded state 34, as shown in FIGS. 3 and 4, to collect the emboli 24.


Next, as shown in FIG. 5, the expandable balloon 64 is deflated back into the deflated state 58 by extracting the fluid therefrom via the tubular body 62. Although the expandable balloon 64 no longer contacts the stenosis 66 after the deflation of thereof, the body vessel 22 typically still defines a generally unobstructed flow path. More specifically, the body vessel 22 walls in the area of the stenosis 66 substantially remain in an expanded state 59 and the blood stream 25 is substantially unobstructed. While the expandable balloon 64 is being deflated the filter 26 preferably still remains in the expanded state 34, as shown in FIG. 5, to collect emboli 24 that may be released into the blood stream 25.


As shown in FIG. 6, the filter 26 is then collapsed into the collapsed state 32 by an extraction sleeve 84. For example, the extraction sleeve 84 is advanced from a non-extraction position 86 (FIGS. 1-5) to an extraction position 88 to radially compress the filter 26. When in the non-extraction position 86, the extraction sleeve 84 is located distally of the filter 26. Conversely, when in the retraction position 88, the extraction sleeve 84 is disposed about the filter 26.


As is known in the art, the term “proximal” refers to the portion of the embolic protection device 20 that is not positioned within the body vessel 22 during normal use of the embolic protection device 20 and the term “distal” refers to the opposing portion of the embolic protection device 20, which may be positioned within the body vessel 22. Therefore, when the extraction sleeve 84 is moved from the non-extraction position 86 to the extraction position 88, the device 20 is moved proximally. Similarly, when the embolic protection device 20 is extracted from the body vessel 22, it is likewise moved proximally. In this configuration, the filter 26 is collapsed into the extraction position 88 in the same direction as the direction of travel during extraction, thereby potentially reducing the likelihood that emboli escape from the filter 26 while the filter 26 is being collapsed.


The extraction sleeve 84 is preferably moved with respect to the filter 26 via an extraction control wire 90 that is able to be retracted with respect to the filter control wire 68, as will be discussed in more detail below.


When the filter 26 is in the collapsed state 32, the diameter is substantially reduced, thereby effectively securing the emboli 24 in the respective filters 26a, 26b, 26c and reducing the overall diameter of the embolic protection device 20 so that it can be retracted through the outer catheter 60. The assembly 54 discussed herein may be used with any other suitable procedure.


In the embodiment shown in FIGS. 1-6, both the delivery sleeve 70 and the extraction sleeve 84 are hollow tubes made of any suitable material, such as mesh/net cloth, nylon, polymeric material, Teflon, or a woven mixture of any of the above materials. The sleeves 70, 84 are preferably radially flexible enough so as to negotiate the winding paths of the blood vessel 22, but are preferably not radially flexible enough so that they substantially radially expand when disposed around the filter so as to fail to effectively secure the emboli 24. The sleeves 70, 84 shown in FIGS. 1-6 have equal diameters so that the filter 26 in the collapsed state 32 shown in FIG. 1 has the same diameter as the filter 26 in the collapsed state 32 shown in FIG. 6. However, the filter 26 may have different diameters during the respective stages of the procedure.


Referring to FIGS. 9-11, the configuration of the filter control wire 68, the delivery control wire 78, and the extraction control wire 90 will now be discussed in more detail. The filter control wire 68 shown in the figures is formed of a tightly-coiled wire 92 having an axial stiffness and a radial flexibility that are conducive to navigation of tortuous pathways of the blood vessel 22. The filter control wire 68 may be made of any suitable material or combination of materials that are biocompatible or capable of being made biocompatible, such as stainless steel, other biologically compatible metals, polymers, plastics, alloys (including super-elastic alloys), or composite materials. The filter control wire 68 in the figures is a single coiled wire 92 wound at a pitch angle suitable for a desired flexibility. A relatively steep pitch angle, which is defined as being generally close to 90 degrees, is typically more flexible than a generally shallow pitch angle. The pitch angle of the coiled wire 92 may vary along the length of the filter control wire 68 to affect the radial stiffness thereof. In an alternative design, the filter control wire 68 may be a multiple filament, helically wound row of wires, similar to that disclosed in the U.S. Patent Application entitled “ENDOVASCULAR MEDICAL DEVICE WITH PLURALITY OF WIRES” having Ser. No. 10/615,314, which was filed on Jul. 7, 2003 and which is incorporated herein by reference.


The coiled wire 92 defines a hollow conduit 94 extending along the filter control wire 68 and providing guidance for portions of the embolic protection device 20. For example, the delivery control wire 78 and the extraction control wire 90 extend at least partially along the conduit 94 for guidance through the blood vessel 22 and for space efficiency. More specifically, as shown in FIG. 9, the delivery control wire 78 is located within the conduit 94 along a first portion 96 of the filter control wire 68, is located outside of the conduit 94 along a second portion 98 of the filter control wire 68, and extends out of the conduit 94 at a transition point 100 between a pair of adjacent coil sections. The transition point 100 for the delivery control wire 78 is preferably located proximal to the non-delivery position 74 so that the delivery sleeve 70 may be easily retracted to the non-delivery position 74. Similarly, a transition point for the extraction control wire 90 is preferably located proximal to the non-extraction position 86 so that the extraction sleeve 84 may be easily retracted to the non-extraction position 86.


Because the delivery sleeve 70 and the extraction sleeve 84 are only moving in a proximal direction with respect to the filter 26 during the above-described treatment, the respective sleeves 70, 84 may be controlled by pulling on the respective control wires 78, 90 and/or pushing on the filter control wire 68. Therefore, because the respective control wires 78, 90 are only pulled and not pushed, they do not require a relatively high axial stiffness compared to the filter control wire 68 and thereby do not require a relatively high cross-sectional area compared to the filter control wire 68. This configuration is especially beneficial because the delivery control wire 78 and the extraction control wire 90 are more easily positioned within the conduit 94 to reduce the space of the embolic protection device 20.


In one example, referring to FIGS. 10 and 11, the filter control wire 68 has a generally circular cross-section with an outer diameter 102 of 0.13 inches and an inner diameter 104 of 0.06 inches. In this example, the delivery control wire 78 has a generally rectangular cross-section with a thickness 106 of 0.001 inches and a height 108 of 0.003 inches. Furthermore, the extraction control wire 90 has a generally rectangular cross-section with a thickness 110 of 0.001 inches and a height 112 of 0.003 inches. However, control wires 68, 78, 90 with any suitable dimensions and configurations may be used.


Referring now to FIG. 12, an alternative embodiment of the present invention is shown. In this embodiment, an embolic protection device 220 is shown with an extraction element 284 that is an extraction wire 285 defining a coil 287. As with the embolic protection device shown in FIGS. 1-6, the extraction element 284 is movable between a non-extraction position 286 (FIG. 12) and an extraction position 288 (FIG. 13). More specifically, when in the non-extraction position 286, the extraction wire 285 is spaced distally of the filter 226 so that the filter elements 226a, 226b, 226c are able to expand into an expanded state 234.


When in the extraction position 288, the extraction wire 285 is disposed about the filter 226 so that the filter elements 226a, 226b, 226c are compressed into a collapsed state 232 having a relatively small collapsed diameter 289 for extraction from the blood vessel 222. The extraction wire 285 is moved from the non-extraction position 286 to the extraction position 288 by an extraction control wire 290. For example, a physician is able to pull on the extraction control wire 290 while holding the filter control wire 68 steady. The embolic protection device 220 shown in FIGS. 12 and 13 is especially advantageous because the coil 287 can be stored in an axially compressed state when in the non-extraction position 286 to reduce the axial length of the embolic protection device 220.


Referring now to FIG. 14, another alternative embodiment of the present invention is shown. In this embodiment, an embolic protection device 320 is shown with an extraction element 384 that includes a plurality of extraction wires 385, each defining a single loop 387. As with the embolic protection device shown in FIGS. 12 and 13, the extraction element 384 is movable between a non-extraction position 386 (FIG. 14) and an extraction position 388 (FIG. 15). More specifically, when in the non-extraction position 386, the extraction wire 385 is spaced distally of the filter 326 so that the filter elements 326a, 326b, 326c are able to expand into an expanded state 334.


When in the extraction position 388, the extraction wire 385 is disposed about the filter 326 so that the filter elements 326a, 326b, 326c are compressed into a collapsed state 332 having a relatively small collapsed diameter 289 for extraction from the blood vessel 322. More specifically, the extraction wire 385 includes a single loop 387a that surrounds the first filter element 326a so that the first filter element 326a is compressed into a collapsed state 332 for extraction from the blood vessel 322. Similarly, two other extraction wires 385b, 385c define single loops 387b, 387c that surround the second and third filter elements 326b, 326c respectively so that the filter elements 326b, 326c are also compressed into the collapsed state 332. The three extraction wires 385a, 385b, 385c may be controlled by a single control wire so that they can be simultaneously deployed into the extraction position 388, or they can be independently controlled. This configuration is especially advantageous because the three loops 387a, 387b, 387c can be stored in an axially compressed state when in the non-extraction position 386 to reduce the axial length of the embolic protection device 320. The extraction wire 385 is moved from the non-extraction position 386 to the extraction position 388 by an extraction control wire 390. For example, a physician is able to pull on the extraction control wire 390 while holding the filter control wire 368 steady.


The extraction element 384 may alternatively be positioned such that, when in the non-extraction position 386, each of the three loops 387a, 387b, 387c is positioned immediately distally one of the filters 326a, 326b, 326c. More specifically, when in the non-extraction position 386, the first loop 387a is positioned between the first and second filters 326a, 326b; the second loop 387b is positioned between the second and third filters 326b, 326c; and the third loop 387c is positioned immediately distally of the third filter 326c.


Referring now to FIG. 16, yet another alternative embodiment of the present invention is shown. In this embodiment, an embolic protection device 420 is shown in an expanded state having first, second, and third filter elements 426a, 426b, 426c positioned in tandem along a center core wire 500 that extends along a longitudinal axis 502. The filter elements 426a, 426b, 426c overlap each other along the longitudinal axis 502 so that the first and second filter elements 426a, 426b define an overlapping distance 504 and the second and third filter elements 426b, 426c define a second overlapping distance 506.


Furthermore, the respective filter elements 426a, 426b, 426c are preferably connected to each other to stabilize the embolic protection device 420 and to prevent emboli from flowing around the embolic protection device. More specifically, a proximal end 508 of the second filter element 426b is connected to an outer surface 510 of the first filter element 426a and a proximal end 512 of the third filter element 426c is connected to an outer surface 514 of the second filter element 426b. The emboli 24 that flow into the mouth portion of the embolic protection device 420 therefore remain within one of the filters element 426a, 426b, 426c even after flowing through an opening in the proximally-located filter element. In other words, the embolic protection device 420 shown in FIG. 16 needs only a single seal with the blood vessel 22—the seal at the proximal end 518 of the first filter element 426a—rather than three seals between the respective filter elements and the blood vessel 22. Furthermore, because the actual filter elements 426a, 426b, 426c are connected to each other, no additional sleeve is needed to surround the embolic protection device 420 to keep the emboli within a filter element at all times. The respective filter elements 426a, 426b, 426c are connected with each other by any appropriate means, such as an adhesive, a string or cable, or a bioscaffold material.


In this design, the respective filter elements 426a, 426b, 426c cooperate to define a generally constant outer diameter 516 between a proximal end 518 of the first filter element 426a and a distal end 520 of the third filter element 426c. The substantially constant outer diameter 516 of the filter elements 426a, 426b, 426c improves the sealing connection between the embolic protection device 420 and the blood vessel 22, thereby reducing the number of emboli 24 that flow past the embolic protection device 420. Furthermore, the connections between the respective filter elements 426a, 426b, 426c prevent the individual filter elements from undesirably turning within the blood vessel 22 and otherwise stable the embolic protection device 420.


The first filter element 426a defines a first plurality of openings 522 so that the first filter element 426a is designed to capture relatively large emboli 24a. Additionally, the second filter element 426b defines a second plurality of openings 524 that are smaller than the first plurality of openings 522 so that the second filter element 426b is designed to capture medium-sized emboli 24b. Similarly, the third filter element 426c defines a third plurality of openings 526 that are smaller than the second plurality of openings 524 so that the third filter element 426c is designed to capture relatively small emboli 24c. As with the design shown in FIG. 2, the varying-size openings in the three filter elements 426a, 426b, 426c are beneficial for reducing the cross-sectional area of the filter 426 when the emboli 24 are trapped therewithin. In other words, each of the filter elements 426a, 426b, 426c is able to collect a generally equal volume of emboli 24, thereby equally distributing the emboli 24 among the filter elements 426a, 426b, 426c.


The center core wire 500 of the embolic protection device 420 guides the respective filter elements 426a, 426b, 426c within the blood vessel 22 and properly positions the elements 426a, 426b, 426c with respect to each other. For example, each of the filter elements 426a, 426b, 426c includes a sliding sleeve 528, 530, 532 attached to the distal end thereof 534, 536, 520 that receives and that is freely slidable along the center core wire 500. Therefore, the sliding sleeves 528, 530, 532 are able to slide along the center core wire 500 during deployment into the blood vessel 22 and during extraction therefrom, as will be discussed in further detail below. Furthermore, the sliding sleeves 528, 530, 532 radially position the filter elements 426a, 426b, 426c within the blood vessel 22 during emboli collection.


The embolic protection device 420 is moved between an expanded state 434 (shown in FIG. 16) and a collapsed state 432 (FIG. 17) by a control sleeve 538 and a connecting member 540. For example, the control sleeve 538 receives the center core wire 500 and is rotatable thereon to adjust the embolic protection device 420 between the expanded state 434 and the collapsed state 432. More specifically, the control sleeve 538 is connected to the proximal end 518 of the first filter element 426a by the connecting member 540 so that the proximal ends of the filter elements 426a, 426b, 426c each rotate about the center core wire 500 along with the control sleeve 538. The respective sliding sleeves 528, 530, 532 at the distal ends of the filter elements 426a, 426b, 426c are preferably disposed around the center core wire 500 so that they are permitted to slide axially therealong but not permitted to rotate therearound. For example, the sliding sleeves 528, 530, 532 may each have tabs extending into slots formed along the length of the center core wire 500 to prevent rotation of the sliding sleeves 528, 530, 532. Therefore, as the proximal portions of the filter elements 426a, 426b, 426c each rotate about the center core wire 500, the sliding sleeves 528, 530, 532 and the distal portions of the filter elements 426a, 426b, 426c are generally prevented from rotating about the center core wire 500, thereby causing the embolic protection device 420 to twist and collapse into an extraction position 488 as shown in FIG. 17.


In an alternative design, the filter elements 426a, 426b, 426c include frame portions made of a relatively elastic material, such as a super elastic metal, to ease the opening and closing of the embolic protection device 420. In yet another design, a delivery sleeve and/or an extraction sleeve are included to deliver and extract the emboli protection device 420, as described above.


It is therefore intended that the foregoing detailed description be regarded as illustrative rather than limiting, and that it be understood that it is the following claims, including all equivalents, that are intended to define the spirit and scope of this invention.

Claims
  • 1. An embolic protection device for filtering emboli in a body vessel, the device comprising: a filter having a plurality of openings formed therethrough, the filter having an expanded state and a collapsed state, wherein the filter has a proximal expandable end and a distal non-expandable end;a delivery element comprising a delivery sleeve, the delivery sleeve configured to be movable with respect to the filter between a delivery position, where the delivery sleeve is disposed about at least a portion of the filter so that the filter is in the collapsed state, and a non-delivery position, where the delivery sleeve is located proximally from the proximal expandable end of the filter, the delivery sleeve having a proximal end and a distal end, each of the proximal and distal ends of the delivery sleeve having a first position in the delivery position and a second position in the non-delivery position; andan extraction element separate from the delivery sleeve and configured to be movable with the filter and independently of the filter between a non-extraction position, where the extraction element is located distally of the distal non-expandable end of the filter, and an extraction position, where the extraction element is disposed around at least a portion of the filter so that the filter is in the collapsed state, the extraction element including a proximal end and a distal end, each of the proximal and distal ends of the extraction element having a first position in the non-extraction position and a second position in the extraction position, the extraction element being movable relative to the delivery sleeve,wherein the extraction element is located distally from the filter when the delivery sleeve is disposed about at least a portion of the filter and wherein the delivery sleeve is located proximally from the filter when the extraction element is disposed around at least a portion of the filter.
  • 2. An embolic protection device as in claim 1, wherein the extraction element includes an extraction sleeve.
  • 3. An embolic protection device as in claim 1, wherein the extraction element includes an extraction wire defining a loop.
  • 4. An embolic protection device as in claim 3, wherein the extraction wire defines a plurality of closed loops.
  • 5. An embolic protection device as in claim 4, wherein each of the plurality of loops is movable with respect to each other.
  • 6. An embolic protection device as in claim 3, wherein the extraction wire defines a coiled wire.
  • 7. An embolic protection device as in claim 1, wherein the filter includes a first filter element and a second filter element spaced apart from each other.
  • 8. An embolic protection device as in claim 7, wherein the first filter element defines a plurality of first filter openings, the second filter element defines a plurality of second filter openings, and each of the first filter openings are larger than each of the second filter openings.
  • 9. An embolic protection device as in claim 7, wherein the filter includes a third filter element spaced apart from the first and the second filter elements.
  • 10. An embolic protection device as in claim 1, further comprising: a filter control wire coupled with the filter and configured to control the position thereof;an extraction control wire coupled with the extraction element and configured to control the position thereof; anda delivery control wire coupled with the delivery element and configured to control the position thereof.
  • 11. An embolic protection device as in claim 10, wherein the filter control wire is a hollow wire defining a conduit receiving at least a portion of the extraction control wire and at least a portion of the delivery control wire.
  • 12. An embolic protection device as in claim 10, wherein an outer diameter of the filter control wire is substantially greater than an outer diameter of the extraction control wire and is substantially greater than an outer diameter of the delivery control wire.
  • 13. An embolic protection device for filtering emboli in a body vessel, the device comprising: a filter having a plurality of openings formed therethrough, the filter having an expanded state and a collapsed state, wherein the filter has a proximal expandable end and a distal non-expandable end;a delivery element comprising a delivery sleeve, the delivery sleeve configured to be movable with respect to the filter between a delivery position, where the delivery sleeve is disposed about at least a portion of the filter so that the filter is in the collapsed state, and a non-delivery position, where the delivery sleeve is located proximally from the proximal expandable end of the filter the delivery sleeve having a proximal end and a distal end, each of the proximal and distal ends of the delivery sleeve having a first position in the delivery position and a second position in the non-delivery position; andan extraction element separate from the delivery sleeve and configured to be movable with the filter and independently of the filter between a non-extraction position, where the extraction element is located distally of the distal non-expandable end of the filter, and an extraction position, where the extraction element is disposed around at least a portion of the filter so that the filter is in the collapsed state, the extraction element including a proximal end and a distal end, each of the proximal and distal ends of the extraction element having a first position in the non-extraction position and a second position in the extraction position,wherein the extraction element is located distally from the filter when the delivery sleeve is disposed about at least a portion of the filter and wherein the delivery sleeve is located proximally from the filter when the extraction element is disposed around at least a portion of the filter,wherein the filter includes a first filter element and a second filter element spaced apart from each other,wherein the first filter element defines a plurality of first filter openings and the second filter element defines a plurality of second filter openings, wherein the first filter openings are decreasing in size from a proximal portion to a distal portion of the first filter and the second filter openings are decreasing in size from a proximal portion to a distal portion of the second filter.
  • 14. An assembly for removing emboli from a body vessel, the assembly comprising: an inflatable catheter having a deflated state to facilitate delivery of the inflatable catheter within the body vessel and an expanded state to facilitate expansion of a wall of the body vessel, thereby potentially releasing the emboli into the body vessel;an outer catheter for delivering the inflatable catheter into the body vessel;an embolic protection device positioned distally of the inflatable catheter for collecting the emboli, the embolic protection device including: a filter having a plurality of openings formed therethrough, the filter having an expanded state and a collapsed state, wherein the filter has a proximal expandable end and a distal non-expandable end;a delivery element comprising a delivery sleeve, the delivery sleeve configured to be movable with respect to the filter between a delivery position, where the delivery sleeve is disposed about at least a portion of the filter so that the filter is in the collapsed state, and a non-delivery position, where the delivery sleeve is located proximally from the proximal expandable end of the filter, the delivery sleeve having a proximal end and a distal end, each of the proximal and distal ends of the delivery sleeve having a first position in the delivery position and a second position in the non-delivery position; andan extraction element separate from the delivery sleeve and configured to be movable with the filter and independently of the filter between a non-extraction position, where the extraction element is located distally of distal non-expandable end the filter, and an extraction position, where the extraction element is disposed about at least a portion of the filter so that the filter is in the collapsed state, the extraction element including a proximal end and a distal end, each of the proximal and distal ends of the extraction element having a first position in the non-extraction position and a second position in the extraction position, the extraction element being movable relative to the delivery sleeve,wherein the extraction element is located distally from the filter when the delivery sleeve is disposed about at least a portion of the filter and wherein the delivery sleeve is located proximally from the filter when the extraction element is disposed around at least a portion of the filter.
  • 15. An assembly as in claim 14, wherein the filter of the embolic protection device includes a first filter element and a second filter element spaced apart from each other.
  • 16. An assembly as in claim 14, the embolic protection device further including: a filter control wire coupled with the filter and configured to control the position thereof;an extraction control wire coupled with the extraction element and configured to control the position thereof; anda delivery control wire coupled with the delivery element and configured to control the position thereof.
CROSS-REFERENCE TO RELATED APPLICATION

This patent application claims the benefit under 35 U.S.C. §119(e) of U.S. provisional patent application Ser. No. 60/723,255, filed Oct. 3, 2005 and entitled EMBOLIC PROTECTION DEVICE, the entire contents of which are incorporated herein by reference.

US Referenced Citations (859)
Number Name Date Kind
3108593 Glassman Oct 1963 A
3334629 Cohn Aug 1967 A
3472230 Fogarty Oct 1969 A
3547103 Cook Dec 1970 A
3635223 Klieman Jan 1972 A
3923065 Nozick et al. Dec 1975 A
3952747 Kimmell, Jr. Apr 1976 A
3978863 Fettel et al. Sep 1976 A
3996938 Clark, III Dec 1976 A
4425908 Simon Jan 1984 A
4456000 Schjeldahl et al. Jun 1984 A
4494531 Gianturco Jan 1985 A
4548206 Osborne Oct 1985 A
4561439 Bishop et al. Dec 1985 A
4562039 Koehler Dec 1985 A
4604094 Shook Aug 1986 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4643184 Mobin-Uddin Feb 1987 A
4646736 Auth Mar 1987 A
4650472 Bates Mar 1987 A
4665906 Jervis May 1987 A
4669464 Sulepov Jun 1987 A
4688553 Metals Aug 1987 A
4723549 Wholey et al. Feb 1988 A
4727873 Mobin-Uddin Mar 1988 A
4732152 Wallsten et al. Mar 1988 A
4817600 Herms et al. Apr 1989 A
4824435 Giesy et al. Apr 1989 A
4832055 Palestrant May 1989 A
4846794 Hertzer Jul 1989 A
4848343 Wallsten et al. Jul 1989 A
4873978 Ginsburg Oct 1989 A
4943297 Saveliev et al. Jul 1990 A
4957501 Lahille et al. Sep 1990 A
4990156 Lefebvre Feb 1991 A
4998916 Hammerslag et al. Mar 1991 A
5053008 Bajaj Oct 1991 A
5059205 El-Nounou et al. Oct 1991 A
5069226 Yamauchi et al. Dec 1991 A
5078726 Kreamer Jan 1992 A
5100423 Fearnot Mar 1992 A
5108418 Lefebvre Apr 1992 A
5108419 Reger et al. Apr 1992 A
5112347 Taheri May 1992 A
5129890 Bates et al. Jul 1992 A
5133733 Rasmussen et al. Jul 1992 A
5147379 Sabbaghian et al. Sep 1992 A
5152777 Goldberg Oct 1992 A
5160342 Reger Nov 1992 A
5163927 Woker et al. Nov 1992 A
5203772 Hammerslag et al. Apr 1993 A
5234458 Metais Aug 1993 A
5242462 El-Nounou Sep 1993 A
5243996 Hall Sep 1993 A
5251640 Osborne Oct 1993 A
5263964 Purdy Nov 1993 A
5300086 Gory et al. Apr 1994 A
5324304 Rasmussen Jun 1994 A
5329942 Gunther et al. Jul 1994 A
5344427 Cottenceau et al. Sep 1994 A
5350397 Palermo et al. Sep 1994 A
5350398 Pavcnik et al. Sep 1994 A
5364345 Lowery et al. Nov 1994 A
5370657 Irie Dec 1994 A
5375612 Cottenceau et al. Dec 1994 A
5383887 Nadal Jan 1995 A
5413586 Dibie et al. May 1995 A
5415630 Gory et al. May 1995 A
5417708 Hall et al. May 1995 A
5451233 Yock Sep 1995 A
5458573 Summers Oct 1995 A
5522881 Lentz Jun 1996 A
5527338 Purdy Jun 1996 A
5531788 Dibie et al. Jul 1996 A
5549551 Peacock et al. Aug 1996 A
5549626 Miller et al. Aug 1996 A
5556414 Turi Sep 1996 A
5562698 Parker Oct 1996 A
5571135 Fraser et al. Nov 1996 A
5591195 Taheri et al. Jan 1997 A
5601595 Smith Feb 1997 A
5624461 Mariant Apr 1997 A
5626605 Irie et al. May 1997 A
5630797 Diedrich et al. May 1997 A
5634942 Chevillon et al. Jun 1997 A
5649953 Lefebvre Jul 1997 A
5662703 Yurek et al. Sep 1997 A
5669933 Simon et al. Sep 1997 A
5681347 Cathcart et al. Oct 1997 A
5690642 Osborne et al. Nov 1997 A
5690667 Gia Nov 1997 A
5693067 Purdy Dec 1997 A
5693087 Parodi Dec 1997 A
5695518 Laerum Dec 1997 A
5695519 Summers et al. Dec 1997 A
5700253 Parker Dec 1997 A
5709704 Nott et al. Jan 1998 A
5713853 Clark et al. Feb 1998 A
5720764 Naderlinger Feb 1998 A
5725550 Nadal Mar 1998 A
5738667 Solar Apr 1998 A
5746767 Smith May 1998 A
5755772 Evans et al. May 1998 A
5755790 Chevillon et al. May 1998 A
5766203 Imran et al. Jun 1998 A
5769816 Barbut et al. Jun 1998 A
5769871 Mers et al. Jun 1998 A
5795322 Boudewijn Aug 1998 A
5800457 Gelbfish et al. Sep 1998 A
5800525 Bachinski et al. Sep 1998 A
5810874 Lefebvre Sep 1998 A
5814027 Hassett et al. Sep 1998 A
5814064 Daniel et al. Sep 1998 A
5820592 Hammerslag Oct 1998 A
5827324 Cassell et al. Oct 1998 A
5830230 Berryman et al. Nov 1998 A
5836968 Simon et al. Nov 1998 A
5836969 Kim et al. Nov 1998 A
5846260 Maahs Dec 1998 A
5853420 Chevillon et al. Dec 1998 A
5876367 Kaganov et al. Mar 1999 A
5893869 Barnhart et al. Apr 1999 A
5895391 Farnholtz Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5895410 Forber et al. Apr 1999 A
5908435 Samuels Jun 1999 A
5910154 Tsugita et al. Jun 1999 A
5911702 Romley et al. Jun 1999 A
5911704 Humes Jun 1999 A
5911717 Jacobsen et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5919224 Thompson et al. Jul 1999 A
5925062 Purdy Jul 1999 A
5925063 Khosravi Jul 1999 A
5928260 Chine et al. Jul 1999 A
5928261 Ruiz Jul 1999 A
5938683 Lefebvre Aug 1999 A
5941896 Kerr Aug 1999 A
5944728 Bates Aug 1999 A
5947985 Imran Sep 1999 A
5947995 Samuels Sep 1999 A
5948017 Taheri Sep 1999 A
5951567 Javier, Jr. et al. Sep 1999 A
5954741 Fox Sep 1999 A
5954742 Osypka Sep 1999 A
5954745 Gertler et al. Sep 1999 A
5968057 Taheri Oct 1999 A
5968071 Chevillon et al. Oct 1999 A
5972019 Engelson et al. Oct 1999 A
5976162 Doan et al. Nov 1999 A
5976172 Homsma et al. Nov 1999 A
5980555 Barbut et al. Nov 1999 A
5984947 Smith Nov 1999 A
5984965 Knapp et al. Nov 1999 A
5989281 Barbut et al. Nov 1999 A
6001118 Daniel et al. Dec 1999 A
6007557 Ambrisco et al. Dec 1999 A
6007558 Ravenscloth et al. Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6013093 Nott et al. Jan 2000 A
6015424 Rosenbluth et al. Jan 2000 A
6027520 Tsugita et al. Feb 2000 A
6036717 Mers Kelly et al. Mar 2000 A
6036720 Abrams et al. Mar 2000 A
6042598 Tsugita et al. Mar 2000 A
6051014 Jang Apr 2000 A
6051015 Maahs Apr 2000 A
6053932 Daniel et al. Apr 2000 A
6059745 Gelbfish May 2000 A
6059814 Ladd May 2000 A
6063113 Kavteladze et al. May 2000 A
6066158 Engelson et al. May 2000 A
6068645 Tu May 2000 A
6074357 Kaganov et al. Jun 2000 A
6077274 Ouchi et al. Jun 2000 A
6080178 Meglin Jun 2000 A
6083239 Addis Jul 2000 A
6086577 Ken et al. Jul 2000 A
6086605 Barbut et al. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096053 Bates Aug 2000 A
6096070 Ragheb et al. Aug 2000 A
6099549 Bosma et al. Aug 2000 A
6106497 Wang Aug 2000 A
6126672 Berryman et al. Oct 2000 A
6126673 Kim et al. Oct 2000 A
6129739 Khosravi Oct 2000 A
6136016 Barbut et al. Oct 2000 A
6146396 Konya et al. Nov 2000 A
6146404 Kim et al. Nov 2000 A
6152931 Nadal et al. Nov 2000 A
6152946 Broome et al. Nov 2000 A
6152947 Ambrisco et al. Nov 2000 A
6156061 Wallace et al. Dec 2000 A
6156062 McGuinness Dec 2000 A
6159230 Samuels Dec 2000 A
6165179 Cathcart et al. Dec 2000 A
6165198 McGurk et al. Dec 2000 A
6165199 Barbut Dec 2000 A
6165200 Tsugita et al. Dec 2000 A
6168579 Tsugita et al. Jan 2001 B1
6168603 Leslie et al. Jan 2001 B1
6168610 Marin et al. Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6171328 Addis Jan 2001 B1
6174318 Bates et al. Jan 2001 B1
6179851 Barbut et al. Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6179860 Fulton, III et al. Jan 2001 B1
6179861 Khosravi et al. Jan 2001 B1
6187025 Machek Feb 2001 B1
6193739 Chevillon et al. Feb 2001 B1
6203561 Ramee et al. Mar 2001 B1
6206931 Cook et al. Mar 2001 B1
6214025 Thistle et al. Apr 2001 B1
6214026 Lepak et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6224620 Maahs May 2001 B1
6231588 Zadno-Azizi May 2001 B1
6231589 Wessman et al. May 2001 B1
6235044 Root et al. May 2001 B1
6235045 Barbut et al. May 2001 B1
6238412 Dubrul et al. May 2001 B1
6241746 Bosma et al. Jun 2001 B1
6245012 Kleshinski Jun 2001 B1
6245087 Addis Jun 2001 B1
6245088 Lowery Jun 2001 B1
6245089 Daniel et al. Jun 2001 B1
6251092 Qin et al. Jun 2001 B1
6251122 Tsukernik Jun 2001 B1
6254550 McNamara et al. Jul 2001 B1
6254633 Pinchuk et al. Jul 2001 B1
6258026 Ravenscroft et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6264672 Fisher Jul 2001 B1
6267776 O'Connell Jul 2001 B1
6267777 Bosma et al. Jul 2001 B1
6273900 Nott et al. Aug 2001 B1
6273901 Whitcher et al. Aug 2001 B1
6277125 Barry et al. Aug 2001 B1
6277126 Barry et al. Aug 2001 B1
6277138 Levinson et al. Aug 2001 B1
6277139 Levinson et al. Aug 2001 B1
6280451 Bates et al. Aug 2001 B1
6287321 Jang Sep 2001 B1
6290710 Cryer et al. Sep 2001 B1
6299604 Ragheb et al. Oct 2001 B1
6306163 Fitz Oct 2001 B1
6309399 Barbut et al. Oct 2001 B1
6312444 Barbut Nov 2001 B1
6319268 Ambrisco et al. Nov 2001 B1
6325815 Kusleika et al. Dec 2001 B1
6325816 Fulton, III et al. Dec 2001 B1
6328755 Marshall Dec 2001 B1
6331183 Suon Dec 2001 B1
6331184 Abrams Dec 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6336934 Gilson et al. Jan 2002 B1
6338739 Datta et al. Jan 2002 B1
6340364 Kanesaka Jan 2002 B2
6342062 Suon et al. Jan 2002 B1
6342063 DeVries et al. Jan 2002 B1
6344048 Chin et al. Feb 2002 B1
6344049 Levinson et al. Feb 2002 B1
6346116 Brooks et al. Feb 2002 B1
6348041 Klint Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350271 Kurz et al. Feb 2002 B1
6355051 Sisskind et al. Mar 2002 B1
6358228 Tubman et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6361546 Khosravi Mar 2002 B1
6361547 Hieshima Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6364896 Addis Apr 2002 B1
6368338 Konya et al. Apr 2002 B1
6371961 Osborne et al. Apr 2002 B1
6371969 Tsugita et al. Apr 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371971 Tsugita et al. Apr 2002 B1
6375670 Greenhalgh Apr 2002 B1
6379374 Hieshima et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6383146 Klint May 2002 B1
6383171 Gifford et al. May 2002 B1
6383174 Eder May 2002 B1
6383193 Cathcart et al. May 2002 B1
6383196 Leslie et al. May 2002 B1
6383205 Samson et al. May 2002 B1
6383206 Gillick et al. May 2002 B1
6391044 Yadav et al. May 2002 B1
6391045 Kim et al. May 2002 B1
6391052 Buirge et al. May 2002 B2
6395014 Macoviak et al. May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6402772 Amplatz et al. Jun 2002 B1
6409742 Fulton, III et al. Jun 2002 B1
6413235 Parodi Jul 2002 B1
6416530 DeVries et al. Jul 2002 B2
6419686 McLeod et al. Jul 2002 B1
6423052 Escano Jul 2002 B1
6423086 Barbut et al. Jul 2002 B1
6425909 Dieck et al. Jul 2002 B1
6428557 Hilaire Aug 2002 B1
6428558 Jones et al. Aug 2002 B1
6428559 Johnson Aug 2002 B1
6432122 Gilson et al. Aug 2002 B1
6436112 Wensel et al. Aug 2002 B2
6436120 Meglin Aug 2002 B1
6436121 Blom Aug 2002 B1
6443926 Kletschka Sep 2002 B1
6443971 Boylan et al. Sep 2002 B1
6443972 Bosma et al. Sep 2002 B1
6443979 Stalker et al. Sep 2002 B1
6447530 Ostrovsky et al. Sep 2002 B1
6447531 Amplatz Sep 2002 B1
6454775 Demarais et al. Sep 2002 B1
6458139 Palmer et al. Oct 2002 B1
6458145 Ravenscroft et al. Oct 2002 B1
6461370 Gray et al. Oct 2002 B1
6468290 Weldon et al. Oct 2002 B1
6468291 Bates et al. Oct 2002 B2
6482222 Bruckheimer et al. Nov 2002 B1
6485456 Kletschka Nov 2002 B1
6485500 Kokish et al. Nov 2002 B1
6485501 Green Nov 2002 B1
6485502 Don Michael et al. Nov 2002 B2
6491712 O'Connor Dec 2002 B1
6494895 Addis Dec 2002 B2
6497709 Heath Dec 2002 B1
6499487 McKenzie et al. Dec 2002 B1
6500166 Zadno Azizi et al. Dec 2002 B1
6500191 Addis Dec 2002 B2
6502606 Klint Jan 2003 B2
6506203 Boyle et al. Jan 2003 B1
6506205 Goldberg et al. Jan 2003 B2
6508826 Murphy et al. Jan 2003 B2
6511492 Rosenbluth et al. Jan 2003 B1
6511496 Huter et al. Jan 2003 B1
6511497 Braun et al. Jan 2003 B1
6511503 Burkett et al. Jan 2003 B1
6514273 Voss et al. Feb 2003 B1
6517559 O'Connell Feb 2003 B1
6520978 Blackledge et al. Feb 2003 B1
6520983 Colgan et al. Feb 2003 B1
6527746 Oslund et al. Mar 2003 B1
6527791 Fisher Mar 2003 B2
6527962 Nadal Mar 2003 B1
6530935 Wensel et al. Mar 2003 B2
6530939 Hopkins et al. Mar 2003 B1
6530940 Fisher Mar 2003 B2
6533770 Lepulu et al. Mar 2003 B1
6533800 Barbut Mar 2003 B1
6537293 Berryman et al. Mar 2003 B1
6537294 Boyle et al. Mar 2003 B1
6537296 Levinson et al. Mar 2003 B2
6537297 Tsugita et al. Mar 2003 B2
6540722 Boyle et al. Apr 2003 B1
6540767 Walak et al. Apr 2003 B1
6540768 Diaz et al. Apr 2003 B1
6544221 Kokish et al. Apr 2003 B1
6544276 Azizi Apr 2003 B1
6544278 Vrba et al. Apr 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6544280 Daniel et al. Apr 2003 B1
6547759 Fisher Apr 2003 B1
6551303 Van Tassel et al. Apr 2003 B1
6551341 Boylan et al. Apr 2003 B2
6551342 Shen et al. Apr 2003 B1
6554849 Jones et al. Apr 2003 B1
6558404 Tsukernik May 2003 B2
6558405 McInnes May 2003 B1
6558406 Okada May 2003 B2
6562058 Seguin et al. May 2003 B2
6565591 Brady et al. May 2003 B2
6569147 Evans et al. May 2003 B1
6569183 Kim et al. May 2003 B1
6569184 Huter May 2003 B2
6575995 Huter et al. Jun 2003 B1
6575996 Denison et al. Jun 2003 B1
6575997 Palmer et al. Jun 2003 B1
6579303 Amplatz Jun 2003 B2
6582396 Parodi Jun 2003 B1
6582447 Patel et al. Jun 2003 B1
6582448 Boyle et al. Jun 2003 B1
6589227 Klint Jul 2003 B2
6589230 Gia et al. Jul 2003 B2
6589263 Hopkins et al. Jul 2003 B1
6589264 Barbut et al. Jul 2003 B1
6589265 Palmer et al. Jul 2003 B1
6589266 Whitcher et al. Jul 2003 B2
6592546 Barbut et al. Jul 2003 B1
6592606 Huter et al. Jul 2003 B2
6592616 Stack et al. Jul 2003 B1
6596011 Johnson et al. Jul 2003 B2
6599275 Fischer, Jr. Jul 2003 B1
6599307 Huter et al. Jul 2003 B1
6599308 Amplatz Jul 2003 B2
6602271 Adams et al. Aug 2003 B2
6602273 Marshall Aug 2003 B2
6602280 Chobotov Aug 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6607506 Kletschka Aug 2003 B2
6610077 Hancock et al. Aug 2003 B1
6611720 Hata et al. Aug 2003 B2
6613074 Mitelberg et al. Sep 2003 B1
6616679 Khosravi et al. Sep 2003 B1
6616680 Thielen Sep 2003 B1
6616681 Hanson et al. Sep 2003 B2
6616682 Joergensen et al. Sep 2003 B2
6620148 Tsugita Sep 2003 B1
6620182 Khosravi et al. Sep 2003 B1
6623450 Dutta Sep 2003 B1
6623506 McGuckin, Jr. et al. Sep 2003 B2
6629953 Boyd Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6635069 Teoh et al. Oct 2003 B1
6635070 Leeflang et al. Oct 2003 B2
6638293 Makower et al. Oct 2003 B1
6638294 Palmer Oct 2003 B1
6638372 Abrams et al. Oct 2003 B1
6641590 Palmer et al. Nov 2003 B1
6641605 Stergiopulos Nov 2003 B1
6645160 Heesch Nov 2003 B1
6645220 Huter et al. Nov 2003 B1
6645221 Richter Nov 2003 B1
6645222 Parodi et al. Nov 2003 B1
6645223 Boyle et al. Nov 2003 B2
6645224 Gilson et al. Nov 2003 B2
6652554 Wholey et al. Nov 2003 B1
6652557 MacDonald Nov 2003 B1
6652558 Patel et al. Nov 2003 B2
6656201 Ferrera et al. Dec 2003 B2
6656202 Papp et al. Dec 2003 B2
6656203 Roth et al. Dec 2003 B2
6656204 Ambrisco et al. Dec 2003 B2
6656351 Boyle Dec 2003 B2
6660021 Palmer et al. Dec 2003 B1
6663613 Evans et al. Dec 2003 B1
6663650 Sepetka et al. Dec 2003 B2
6663651 Krolik et al. Dec 2003 B2
6663652 Daniel et al. Dec 2003 B2
6676682 Tsugita et al. Jan 2004 B1
6679902 Boyle et al. Jan 2004 B1
6689144 Gerberding Feb 2004 B2
6695813 Boyle et al. Feb 2004 B1
6695865 Boyle et al. Feb 2004 B2
6702834 Boylan et al. Mar 2004 B1
6709450 Kang et al. Mar 2004 B2
6712835 Mazzocchi et al. Mar 2004 B2
6716207 Farnholtz Apr 2004 B2
6716231 Rafiee et al. Apr 2004 B1
6726701 Gilson et al. Apr 2004 B2
6730064 Ragheb et al. May 2004 B2
6755856 Fierens et al. Jun 2004 B2
6758855 Fulton, III et al. Jul 2004 B2
6761727 Ladd Jul 2004 B1
6773446 Dwyer et al. Aug 2004 B1
6773448 Kusleika et al. Aug 2004 B2
6774278 Ragheb et al. Aug 2004 B1
6780175 Sachdeva et al. Aug 2004 B1
6793667 Hebert et al. Sep 2004 B2
6793668 Fisher Sep 2004 B1
6833002 Stack et al. Dec 2004 B2
6855154 Abdel-Gawwad Feb 2005 B2
6866677 Douk et al. Mar 2005 B2
6866680 Yassour et al. Mar 2005 B2
6872211 White et al. Mar 2005 B2
6878153 Linder et al. Apr 2005 B2
6896691 Boylan et al. May 2005 B2
6929709 Smith Aug 2005 B2
6932831 Forber Aug 2005 B2
6939361 Kleshinski Sep 2005 B1
6942682 Vrba et al. Sep 2005 B2
6955685 Escamilla et al. Oct 2005 B2
6964670 Shah et al. Nov 2005 B1
6964674 Matsuura et al. Nov 2005 B1
6969396 Krolik et al. Nov 2005 B2
6974469 Broome et al. Dec 2005 B2
6974473 Barclay et al. Dec 2005 B2
6986784 Weiser et al. Jan 2006 B1
6991641 Diaz et al. Jan 2006 B2
7128073 van der Burg et al. Oct 2006 B1
7166120 Kusleika Jan 2007 B2
7174636 Lowe Feb 2007 B2
7189249 Hart et al. Mar 2007 B2
7255687 Huang et al. Aug 2007 B2
7285130 Austin Oct 2007 B2
7306619 Palmer Dec 2007 B1
7371248 Dapolito et al. May 2008 B2
7393358 Malewicz Jul 2008 B2
7604649 McGuckin et al. Oct 2009 B2
7666216 Hogendijk et al. Feb 2010 B2
7708770 Linder et al. May 2010 B2
7731722 Lavelle et al. Jun 2010 B2
7766934 Pal et al. Aug 2010 B2
20010000799 Wessman et al. May 2001 A1
20010001817 Humes May 2001 A1
20010005789 Root et al. Jun 2001 A1
20010007947 Kanesaka Jul 2001 A1
20010011181 DiMatteo Aug 2001 A1
20010011182 Dubrul et al. Aug 2001 A1
20010012951 Bates et al. Aug 2001 A1
20010016755 Addis Aug 2001 A1
20010020175 Yassour et al. Sep 2001 A1
20010023358 Tsukernik Sep 2001 A1
20010025187 Okada Sep 2001 A1
20010031980 Wensel et al. Oct 2001 A1
20010031981 Evans et al. Oct 2001 A1
20010031982 Peterson et al. Oct 2001 A1
20010039431 DeVries et al. Nov 2001 A1
20010039432 Whitcher et al. Nov 2001 A1
20010041908 Levinson et al. Nov 2001 A1
20010041909 Tsugita et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010044632 Daniel et al. Nov 2001 A1
20010044634 Don Michael et al. Nov 2001 A1
20010053921 Jang Dec 2001 A1
20020002383 Sepetka et al. Jan 2002 A1
20020002384 Gilson et al. Jan 2002 A1
20020004667 Adams et al. Jan 2002 A1
20020016564 Courtney et al. Feb 2002 A1
20020016609 Wensel et al. Feb 2002 A1
20020022858 Demond et al. Feb 2002 A1
20020022859 Hogendijk Feb 2002 A1
20020026211 Khosravi et al. Feb 2002 A1
20020026212 Wholey et al. Feb 2002 A1
20020026213 Gilson et al. Feb 2002 A1
20020032460 Kusleika et al. Mar 2002 A1
20020032461 Marshall Mar 2002 A1
20020042626 Hanson et al. Apr 2002 A1
20020042627 Brady et al. Apr 2002 A1
20020045915 Balceta et al. Apr 2002 A1
20020045916 Gray et al. Apr 2002 A1
20020045918 Suon et al. Apr 2002 A1
20020049452 Kurz et al. Apr 2002 A1
20020049468 Streeter et al. Apr 2002 A1
20020052627 Boylan et al. May 2002 A1
20020058904 Boock et al. May 2002 A1
20020058911 Gilson et al. May 2002 A1
20020058963 Vale et al. May 2002 A1
20020058964 Addis May 2002 A1
20020062133 Gilson et al. May 2002 A1
20020062134 Barbut et al. May 2002 A1
20020062135 Mazzocchi et al. May 2002 A1
20020065507 Zadno-Azizi May 2002 A1
20020068954 Foster Jun 2002 A1
20020068955 Khosravi Jun 2002 A1
20020072764 Sepetka et al. Jun 2002 A1
20020072765 Mazzocchi et al. Jun 2002 A1
20020077596 McKenzie et al. Jun 2002 A1
20020082558 Samson et al. Jun 2002 A1
20020082639 Broome et al. Jun 2002 A1
20020087187 Mazzocchi et al. Jul 2002 A1
20020090389 Humes et al. Jul 2002 A1
20020091407 Zadno-Azizi et al. Jul 2002 A1
20020091408 Sutton et al. Jul 2002 A1
20020091409 Sutton et al. Jul 2002 A1
20020095170 Krolik et al. Jul 2002 A1
20020095171 Belef Jul 2002 A1
20020095172 Mazzocchi et al. Jul 2002 A1
20020095173 Mazzocchi et al. Jul 2002 A1
20020095174 Tsugita et al. Jul 2002 A1
20020099405 Yurek et al. Jul 2002 A1
20020099407 Becker et al. Jul 2002 A1
20020099435 Stinson Jul 2002 A1
20020103501 Diaz et al. Aug 2002 A1
20020107541 Vale et al. Aug 2002 A1
20020111647 Khairkhahan et al. Aug 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020111649 Russo et al. Aug 2002 A1
20020116024 Goldberg et al. Aug 2002 A1
20020120226 Beck Aug 2002 A1
20020120286 DoBrava et al. Aug 2002 A1
20020120287 Huter Aug 2002 A1
20020123720 Kusleika et al. Sep 2002 A1
20020123755 Lowe et al. Sep 2002 A1
20020123759 Amplatz Sep 2002 A1
20020123766 Seguin et al. Sep 2002 A1
20020128679 Turovskiy et al. Sep 2002 A1
20020128680 Pavlovic Sep 2002 A1
20020128681 Broome et al. Sep 2002 A1
20020133191 Khosravi et al. Sep 2002 A1
20020133192 Kusleika et al. Sep 2002 A1
20020138094 Borillo et al. Sep 2002 A1
20020138095 Mazzocchi et al. Sep 2002 A1
20020138096 Hieshima Sep 2002 A1
20020138097 Ostrovsky et al. Sep 2002 A1
20020143360 Douk et al. Oct 2002 A1
20020143361 Douk et al. Oct 2002 A1
20020143362 Macoviak et al. Oct 2002 A1
20020151927 Douk et al. Oct 2002 A1
20020151928 Leslie et al. Oct 2002 A1
20020156520 Boylan et al. Oct 2002 A1
20020161389 Boyle et al. Oct 2002 A1
20020161390 Mouw Oct 2002 A1
20020161391 Murphy et al. Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161393 Demond et al. Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020161395 Douk et al. Oct 2002 A1
20020161396 Jang et al. Oct 2002 A1
20020165557 McAlister Nov 2002 A1
20020165573 Barbut Nov 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20020165598 Wahr et al. Nov 2002 A1
20020169472 Douk et al. Nov 2002 A1
20020169474 Kusleika et al. Nov 2002 A1
20020173815 Hogendijk et al. Nov 2002 A1
20020173819 Leeflang et al. Nov 2002 A1
20020177872 Papp et al. Nov 2002 A1
20020177899 Eum et al. Nov 2002 A1
20020183781 Casey et al. Dec 2002 A1
20020183782 Tsugita et al. Dec 2002 A1
20020183783 Shadduck Dec 2002 A1
20020188313 Johnson et al. Dec 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20020193824 Boylan et al. Dec 2002 A1
20020193825 McGuckin et al. Dec 2002 A1
20020193826 McGuckin et al. Dec 2002 A1
20020193827 McGuckin et al. Dec 2002 A1
20020193828 Griffin et al. Dec 2002 A1
20020198561 Amplatz Dec 2002 A1
20030004536 Boylan et al. Jan 2003 A1
20030004537 Boyle et al. Jan 2003 A1
20030004538 Secrest et al. Jan 2003 A1
20030004539 Linder et al. Jan 2003 A1
20030004540 Linder et al. Jan 2003 A1
20030004541 Linder et al. Jan 2003 A1
20030004542 Wensel et al. Jan 2003 A1
20030009146 Muni et al. Jan 2003 A1
20030009189 Gilson et al. Jan 2003 A1
20030009190 Kletschka et al. Jan 2003 A1
20030009191 Wensel et al. Jan 2003 A1
20030014072 Wensel et al. Jan 2003 A1
20030018354 Roth et al. Jan 2003 A1
20030018355 Goto et al. Jan 2003 A1
20030023263 Krolik et al. Jan 2003 A1
20030023264 Dieck et al. Jan 2003 A1
20030023265 Forber Jan 2003 A1
20030032976 Boucck Feb 2003 A1
20030032977 Brady Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030045897 Huter et al. Mar 2003 A1
20030045898 Harrison et al. Mar 2003 A1
20030050662 Michael Mar 2003 A1
20030055452 Joergensen et al. Mar 2003 A1
20030055480 Fischell et al. Mar 2003 A1
20030060843 Boucher Mar 2003 A1
20030060844 Borillo et al. Mar 2003 A1
20030065354 Boyle et al. Apr 2003 A1
20030065355 Weber Apr 2003 A1
20030065356 Tsugita et al. Apr 2003 A1
20030069596 Eskuri Apr 2003 A1
20030073979 Naimark et al. Apr 2003 A1
20030074019 Gray et al. Apr 2003 A1
20030074054 Duerig et al. Apr 2003 A1
20030078614 Salahieh et al. Apr 2003 A1
20030083608 Evans et al. May 2003 A1
20030083692 Vrba et al. May 2003 A1
20030083693 Daniel et al. May 2003 A1
20030088211 Anderson et al. May 2003 A1
20030088266 Bowlin May 2003 A1
20030093110 Vale May 2003 A1
20030093112 Addis May 2003 A1
20030097094 Ouriel et al. May 2003 A1
20030097145 Goldberg et al. May 2003 A1
20030100917 Boyle et al. May 2003 A1
20030100918 Duane May 2003 A1
20030100919 Hopkins et al. May 2003 A1
20030105472 McAlister Jun 2003 A1
20030105484 Boyle et al. Jun 2003 A1
20030105486 Murphy et al. Jun 2003 A1
20030109824 Anderson et al. Jun 2003 A1
20030109897 Walak et al. Jun 2003 A1
20030109916 Michael Jun 2003 A1
20030114879 Euteneuer et al. Jun 2003 A1
20030114880 Hansen et al. Jun 2003 A1
20030120303 Boyle et al. Jun 2003 A1
20030120304 Kaganov et al. Jun 2003 A1
20030125764 Brady et al. Jul 2003 A1
20030125765 Blackledge et al. Jul 2003 A1
20030130680 Russell Jul 2003 A1
20030130681 Ungs Jul 2003 A1
20030130682 Broome et al. Jul 2003 A1
20030130684 Brady et al. Jul 2003 A1
20030130685 Daniel et al. Jul 2003 A1
20030130686 Daniel et al. Jul 2003 A1
20030130687 Daniel et al. Jul 2003 A1
20030130688 Daniel et al. Jul 2003 A1
20030135232 Douk et al. Jul 2003 A1
20030135233 Bates et al. Jul 2003 A1
20030139764 Levinson et al. Jul 2003 A1
20030139765 Patel et al. Jul 2003 A1
20030144685 Boyle et al. Jul 2003 A1
20030144686 Martinez et al. Jul 2003 A1
20030144687 Brady et al. Jul 2003 A1
20030144688 Brady et al. Jul 2003 A1
20030144689 Brady et al. Jul 2003 A1
20030150821 Bates et al. Aug 2003 A1
20030153935 Mialhe Aug 2003 A1
20030153942 Wang et al. Aug 2003 A1
20030153943 Michael et al. Aug 2003 A1
20030153944 Phung et al. Aug 2003 A1
20030153945 Patel et al. Aug 2003 A1
20030158518 Schonholz et al. Aug 2003 A1
20030158574 Esch et al. Aug 2003 A1
20030158575 Boylan et al. Aug 2003 A1
20030163158 White Aug 2003 A1
20030163159 Patel et al. Aug 2003 A1
20030167068 Amplatz Sep 2003 A1
20030167069 Gonzales et al. Sep 2003 A1
20030171769 Barbut Sep 2003 A1
20030171770 Kusleika et al. Sep 2003 A1
20030171771 Anderson et al. Sep 2003 A1
20030171772 Amplatz Sep 2003 A1
20030171800 Bicek et al. Sep 2003 A1
20030171803 Shimon Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030176885 Broome et al. Sep 2003 A1
20030176886 Wholey et al. Sep 2003 A1
20030176887 Petersen Sep 2003 A1
20030176888 O'Connell Sep 2003 A1
20030176889 Boyle et al. Sep 2003 A1
20030181942 Sutton et al. Sep 2003 A1
20030181943 Daniel et al. Sep 2003 A1
20030717769 Barbut Sep 2003
20030187474 Keegan et al. Oct 2003 A1
20030187475 Tsugita et al. Oct 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030191492 Gellman et al. Oct 2003 A1
20030191493 Epstein et al. Oct 2003 A1
20030195554 Shen et al. Oct 2003 A1
20030195555 Khairkhahan et al. Oct 2003 A1
20030195556 Stack et al. Oct 2003 A1
20030199819 Beck Oct 2003 A1
20030199917 Knudson et al. Oct 2003 A1
20030199918 Patel et al. Oct 2003 A1
20030199919 Palmer et al. Oct 2003 A1
20030199920 Boylan et al. Oct 2003 A1
20030199921 Palmer et al. Oct 2003 A1
20030204168 Bosma et al. Oct 2003 A1
20030204202 Palmer et al. Oct 2003 A1
20030204203 Khairkhahan et al. Oct 2003 A1
20030208222 Zadno-Azizi Nov 2003 A1
20030208224 Broome Nov 2003 A1
20030208225 Goll et al. Nov 2003 A1
20030208226 Bruckheimer et al. Nov 2003 A1
20030208227 Thomas Nov 2003 A1
20030208228 Gilson et al. Nov 2003 A1
20030208229 Kletschka Nov 2003 A1
20030208253 Beyer et al. Nov 2003 A1
20030212428 Richter Nov 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212431 Brady et al. Nov 2003 A1
20030212432 Khairkhahan et al. Nov 2003 A1
20030212433 Ambrisco et al. Nov 2003 A1
20030212434 Thielen Nov 2003 A1
20030216774 Larson Nov 2003 A1
20030220665 Eskuri et al. Nov 2003 A1
20030220667 van der Burg et al. Nov 2003 A1
20030225418 Esksuri et al. Dec 2003 A1
20030225435 Hunter et al. Dec 2003 A1
20030229374 Brady et al. Dec 2003 A1
20030233117 Adams et al. Dec 2003 A1
20040006364 Ladd Jan 2004 A1
20040006365 Brady et al. Jan 2004 A1
20040006370 Tsugita Jan 2004 A1
20040015152 Day Jan 2004 A1
20040039412 Isshiki et al. Feb 2004 A1
20040049226 Keegan et al. Mar 2004 A1
20040054394 Lee Mar 2004 A1
20040054395 Lee et al. Mar 2004 A1
20040059372 Tsugita Mar 2004 A1
20040064067 Ward Apr 2004 A1
20040064179 Linder et al. Apr 2004 A1
20040068271 McAlister Apr 2004 A1
20040078044 Kear et al. Apr 2004 A1
20040082962 Demarais et al. Apr 2004 A1
20040088038 Dehnad et al. May 2004 A1
20040093009 Denison et al. May 2004 A1
20040093012 Cully et al. May 2004 A1
20040093016 Root et al. May 2004 A1
20040093059 Lee et al. May 2004 A1
20040098022 Barone May 2004 A1
20040098026 Joergensen et al. May 2004 A1
20040098033 Leeflang et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040102719 Keith et al. May 2004 A1
20040106944 Daniel et al. Jun 2004 A1
20040116831 Vrba Jun 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138696 Drasler et al. Jul 2004 A1
20040153118 Clubb et al. Aug 2004 A1
20040158278 Becker et al. Aug 2004 A1
20040162576 Barbut et al. Aug 2004 A1
20040164030 Lowe et al. Aug 2004 A1
20040167567 Cano et al. Aug 2004 A1
20040176794 Khosravi Sep 2004 A1
20040176833 Pavcnik et al. Sep 2004 A1
20040199203 Oslund et al. Oct 2004 A1
20040204737 Boismier et al. Oct 2004 A1
20040215322 Kerr Oct 2004 A1
20040225321 Krolik et al. Nov 2004 A1
20040236369 Dubrul Nov 2004 A1
20050004663 Llanos et al. Jan 2005 A1
20050021125 Stack et al. Jan 2005 A1
20050027345 Horan et al. Feb 2005 A1
20050038468 Panetta et al. Feb 2005 A1
20050038503 Greenhaigh Feb 2005 A1
20050043743 Dennis Feb 2005 A1
20050043756 Lavelle et al. Feb 2005 A1
20050043780 Gifford et al. Feb 2005 A1
20050049668 Jones et al. Mar 2005 A1
20050126979 Lowe et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050149110 Wholey et al. Jul 2005 A1
20050165480 Jordan et al. Jul 2005 A1
20050177186 Cully et al. Aug 2005 A1
20050177246 Datta et al. Aug 2005 A1
20050197688 Theron et al. Sep 2005 A1
20050209634 Brady et al. Sep 2005 A1
20050216053 Douk et al. Sep 2005 A1
20050217767 Barvosa-Carter et al. Oct 2005 A1
20050228474 Laguna Oct 2005 A1
20060009798 Callister et al. Jan 2006 A1
20060009799 Kleshinski et al. Jan 2006 A1
20060020334 Lashinski et al. Jan 2006 A1
20060030923 Gunderson Feb 2006 A1
20060074474 Theron Apr 2006 A1
20060100544 Ayala et al. May 2006 A1
20060100545 Ayala et al. May 2006 A1
20060161241 Barbut et al. Jul 2006 A1
20060184194 Pal et al. Aug 2006 A1
20060200221 Malewicz Sep 2006 A1
20060229660 Pal et al. Oct 2006 A1
20060264707 Kinney Nov 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20070038241 Pal Feb 2007 A1
20070100372 Schaeffer May 2007 A1
20070112374 Paul, Jr. et al. May 2007 A1
20070129752 Webler et al. Jun 2007 A1
20070149996 Coughlin Jun 2007 A1
20070167974 Cully et al. Jul 2007 A1
20070185521 Bui et al. Aug 2007 A1
20070250108 Boyle et al. Oct 2007 A1
20070288054 Tanaka et al. Dec 2007 A1
20080015518 Huang et al. Jan 2008 A1
20080027481 Gilson et al. Jan 2008 A1
20080103522 Steingisser et al. May 2008 A1
20080154236 Elkins et al. Jun 2008 A1
20080167629 Dann et al. Jul 2008 A1
20080255587 Cully et al. Oct 2008 A1
20080255606 Mitra et al. Oct 2008 A1
20080262337 Falwell et al. Oct 2008 A1
20080275569 Lesh Nov 2008 A1
Foreign Referenced Citations (13)
Number Date Country
34 29 850 Feb 1986 DE
1127556 Aug 2001 EP
1310219 May 2003 EP
1516601 Mar 2005 EP
1557137 Jul 2005 EP
WO 9203097 Mar 1992 WO
WO 9610591 Apr 1996 WO
WO 9916382 Apr 1999 WO
WO 9923976 May 1999 WO
WO 9944510 Sep 1999 WO
WO 0182831 Nov 2001 WO
WO 03077799 Sep 2003 WO
WO 2006138391 Dec 2006 WO
Non-Patent Literature Citations (8)
Entry
Rubicon Embolic Filter, The Next Generation of EM, Rubicon Medical, www.rubiconmed.com.
Heeschen et al., Nature Medicine 7 (2001), No. 7, pp. 833-839.
Johnson et al., Circulation Research 94 (2004), No. 2, pp. 262-268.
International Search Report and Written Opinion for PCT/US2007/020300.
Brochure, “Shuttle Select™ System for Carotid Artery Access,” (2004), pp. 1-3.
Brochure, “Slip-Cath® Angiographic Selective Catheters,” (2004), pp. 1-6.
Finol, E.A. et al., “Performance Assessment of Embolic Protection Filters for Carotid Artery Stenting,” Modelling in Medicine and Biology IV, (2005), vol. 8, pp. 133.
Grummon, David S. et al., Appl. Phys. Lett., 82, 2727 (2003), pp. 2727.
Related Publications (1)
Number Date Country
20070088383 A1 Apr 2007 US
Provisional Applications (1)
Number Date Country
60723255 Oct 2005 US